Related Experiment Video
Updated: Aug 9, 2026
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
Novel therapeutics for systemic lupus erythematosus
Margrit Wiesendanger1, Anfisa Stanevsky, Susan Kovsky
1Department of Medicine, Columbia University Medical Center, New York, New York 10032, USA.
Current Opinion in Rheumatology
|April 4, 2006
Summary
New therapies for systemic lupus erythematosus (SLE) are emerging, focusing on immune modulation and reduced toxicity. These advancements aim to improve treatment efficacy and minimize tissue damage in lupus patients.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by diverse clinical manifestations.
- Current SLE therapies face challenges with efficacy and toxicity, necessitating novel treatment strategies.
Purpose of the Study:
- To review recent therapeutic advancements in SLE.
- To introduce novel therapeutic approaches currently under investigation for SLE.
- To highlight recent discoveries in SLE pathogenesis that inform therapeutic development.
Main Methods:
- Review of preclinical data from murine lupus models.
- Analysis of emerging immunomodulatory compounds and protocols.
- Assessment of therapies entering clinical trials for SLE.
Main Results:
- Numerous therapeutic strategies demonstrate efficacy in preclinical lupus models.
- Inhibitors of cellular signaling pathways and immune repertoire reconstitution protocols are advancing to clinical trials.
- These novel approaches target key mechanisms of autoimmune responses in SLE.
Conclusions:
- Novel SLE therapies must offer superior efficacy and reduced toxicity compared to existing treatments.
- The ultimate goal is to mitigate tissue damage while preserving essential immune function in patients with SLE.
- Advancements in understanding SLE pathogenesis are crucial for guiding the development of next-generation therapeutics.
Related Concept Videos
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Autoimmune Disorders
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Concept and Mechanism of Autoimmune Diseases
The immune system...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...